This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...

But major cuts to federal for Medicaid are a likely outcome of the $1.5-$2 trillion in spending cuts over the next 10 years ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

At what was supposed to be a hearing to discuss PBM reform, some in Congress veered off into discussions about Medicaid and ...

Unlike some other spending cuts, Medicaid cuts will have direct impact on people who voted for Republicans in November 2024, ...

The new lower prices apply to some doses of Zepbound provided in vials but not the autoinjector pens.

Although the importance of ongoing education is known for patients, less than half of those with diabetes receive formal ...

An expert discusses the significance of low-sodium oxybate for patients with narcolepsy patients with and cardiovascular disease and compares the diagnostic criteria and clinical presentations of ...

After receiving the Day 74 letter, which outlines the FDA’s initial assessment of the application, the agency accepted Epioxa ...

The Advisory Committee on Immunization Practices (ACIP) that makes recommendations to the Centers for Disease Control and ...

An expert discusses the key side effects and contraindications associated with antifibrotic agents and how to monitor for and ...

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...